Other languages Valneva Xetra

Equities

Market Closed - Xetra Other stock markets 11:35:37 2024-05-31 EDT			5-day change	1st Jan Change
4.112 ^EUR	+2.24%		+5.33%	-13.41%

05-31	Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee	MT
05-31	EU regulator recommends use of Valneva's chikungunya vaccine	RE

Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee	05-31
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine	05-31
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine	05-31
EU regulator recommends use of Valneva's chikungunya vaccine	05-31
Valneva Se Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer	05-21
Valneva Names New Chief Scientific Officer	05-21
Valneva : nomination d'un directeur scientifique	05-21
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer	05-21
Valneva : nouvelles données positives dans le CHIKV	05-13
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine	05-13
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine	05-13
Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07
Transcript : Valneva SE, Q1 2024 Earnings Call, May 07, 2024	05-07
Valneva : trimestriels dopés par la vente du PRV	05-07
Valneva : Q1 2024 Financial Results	05-07
Valneva : Reports First Quarter 2024 Financial Results and Provides Corporate Updates	05-07
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates	05-07
Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024	05-07
Valneva : Document AMF CP. 2024E960493	04-16
Valneva : Deep Track Biotechnology Master détient moins de 5%	04-11

No results for this search